Biogen Inc.
A biopharmaceutical company focused on the brain and nervous system, Biogen makes treatments for multiple sclerosis, spinal muscular atrophy, ALS, and Alzheimer's — with brands like TYSABRI, SPINRAZA, and the Alzheimer's drug LEQEMBI it co-markets with Eisai. It was founded in 1978 in Geneva by academic scientists (including two future Nobel laureates) and later moved to Cambridge, Massachusetts, where it remains. Its name is a mash-up of "Biotechnology Geneva," and its roots stretch back to the dawn of the biotech industry.
Granted 25.6K
Granted 4.9K · Bought 1.2K
Granted 5.2K · Bought 455
Granted 25.4K
Granted 21.3K
Granted 40.5K
Granted 20.9K · Bought 3
Granted 5.2K · Sold 8.8K
Granted 17.8K · Sold 2.2K
Granted 5.2K
Granted 5.2K
Granted 11.0K
Granted 5.7K
Granted 24.1K · Sold 10.3K
Granted 5.2K
Granted 9.7K
Granted 5.2K
Granted 3.9K
Granted 3.9K
Granted 6.0K
Granted 1.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Alexander Susan HEVP Chief Legal Officer · 22 transactions | — | 58.5K | 25.6K | — | — |
| Dorsa CarolineDirector · 3 transactions | +24.9% | 31.0Kas of Jun 2025 | 4.9K | 1.2K | — |
| Rowinsky Eric KDirector · 4 transactions | +28.1% | 25.8K | 5.2K | 455 | — |
| McDonnell Michael REVP, Chief Financial Officer · 18 transactions | +139.9% | 24.3Kas of Feb 2025 | 25.4K | — | — |
| Gregory GingerEVP, Human Resources · 20 transactions | +163.6% | 22.4K | 21.3K | — | — |
| Viehbacher ChristopherPresident and CEO, Director · 8 transactions | +201.4% | 21.1K | 40.5K | — | — |
| Murphy NicoleHead of Pharm Ops and Tech · 23 transactions | +243.9% | 19.6K | 20.9K | 3 | — |
| Sherwin Stephen ADirector · 4 transactions | -18.9% | 15.2K | 5.2K | — | 8.8K |
| Izzar RachidHead of Global Product Strat. · 21 transactions | +91.8% | 11.8K | 17.8K | — | 2.2K |
| Mantas Jesus BDirector · 3 transactions | +86.2% | 11.3K | 5.2K | — | — |
| Hawkins William ADirector · 3 transactions | +101.3% | 10.4K | 5.2K | — | — |
| Kramer RobinChief Financial Officer · 24 transactions | +127.1% | 9.0K | 11.0K | — | — |
| Freire Maria CDirector · 3 transactions | +184.1% | 8.8K | 5.7K | — | — |
| Singhal PriyaHead of Development · 43 transactions | +175.1% | 8.0K | 24.1K | — | 10.3K |
| Langer SusanDirector · 3 transactions | +1345% | 6.6K | 5.2K | — | — |
| Keeney AdamHead of Corporate Development · 12 transactions | — | 6.4K | 9.7K | — | — |
| Patolawala Monish DDirector · 3 transactions | — | 5.2K | 5.2K | — | — |
| Minor LloydDirector · 2 transactions | — | 3.9K | 3.9K | — | — |
| Pangalos Menelas NDirector · 2 transactions | — | 3.9K | 3.9K | — | — |
| Grogan JaneHead of Research · 10 transactions | — | 3.2K | 6.0K | — | — |
| Godbout SeanChief Accounting Officer · 10 transactions | — | 1.4K | 1.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -19.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.